The use of opioids in emergency departments for the management of migraine pain in adolescents and young adults was found to be common.
Results of a survey on early prescribing patterns of emerging treatments for migraine prophylaxis indicate that clinicians anticipate decreased use of onabotulinumtoxinA and increased use of erenumab for episodic migraine treatment.
Long-term follow-up care for the management of migraine with severe disability using telemedicine was found to have comparable efficacy compared to in-office visits.
A history of migraine in postmenopausal women may not be linked to an increased risk for stroke, myocardial infarction, or composite cardiovascular disease events.
Treatment with monthly subcutaneous injections of galcanezumab 300 mg may not be effective for reducing weekly chronic cluster headache attack frequency.
PHILADELPHIA — Adherence to International Headache Society (IHS) guidelines is most consistent in migraine and cluster headache studies focused on noninvasive vagus nerve stimulation, according to research presented at the American Headache Society 61st Annual Scientific Meeting, held July 11 to 14, 2019, in Philadelphia, Pennsylvania. This systematic review sourced 71 studies from Cochrane Library,…
Eptinezumab treatment for chronic migraine was associated with significant reduction in migraine-related burden on work, home, and social functioning.
Combined stimulation of the occipital and trigeminal nerves using a non-invasive stimulation device was found to be effective for the acute treatment of migraine.
Atogepant was found to be safe and effective for reducing the mean monthly migraine days.
A single dose of oral rimegepant may provide safe, fast, and sustained relief from migraine.
Ubrogepant has demonstrated efficacy in treating acute migraine among individuals for whom triptan has not been effective.
OnabotulinumtoxinA has demonstrated efficacy, safety, and tolerability in treating chronic migraine.
Lacosamide, an anti-epileptic drug that inhibits phosphorylation of collapsing response mediator protein 2 and blocks the release of calcitonin gene-related peptide in the trigeminal system, may be effective in the treatment of chronic migraine.